BiotechTube

Relacorilant + Pembrolizumab

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Adrenocortical Carcinoma

Conditions

Adrenocortical Carcinoma

Trial Timeline

Sep 30, 2020 → Jan 12, 2024

NCT ID
NCT04373265

About Relacorilant + Pembrolizumab

Relacorilant + Pembrolizumab is a phase 1 stage product being developed by Corcept Therapeutics for Adrenocortical Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT04373265. Target conditions include Adrenocortical Carcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT04373265Phase 1Completed

Competing Products

6 competing products in Adrenocortical Carcinoma

See all competitors
ProductCompanyStageHype Score
DS9051bDaiichi SankyoPhase 1
33
OSI-906Astellas PharmaPhase 3
77
Iressa (ZD1839)AstraZenecaPhase 2
52
PembrolizumabMerckPhase 2
52
BGG492NovartisPhase 2
52
SunitinibPfizerPhase 2
51

Other Products from Corcept Therapeutics

Mifepristone 300 MG [Korlym] + Placebo for mifepristoneApproved
80
mifepristonePhase 3
72
mifepristone + placeboPhase 3
72
RelacorilantPhase 3
72
Mifepristone + placeboPhase 3
72